logo

Kempharm, Inc (KMPH)



Trade KMPH now with
  Date
  Headline
11/16/2017 7:30:58 AM KemPharm Completes End-of-Phase 2 Meeting On KP415 With FDA
10/4/2017 7:34:28 AM KemPharm, Genco To Develop Prodrug-Based Therapy For Rare Pediatric Indications Of Tourette’s Syndrome With ADHD
9/20/2017 7:33:53 AM KemPharm Files IND For KP484 For Treatment Of ADHD, An Investigational Prodrug Of Methylphenidate
9/12/2017 7:16:02 AM KemPharm Announces FDRR Process Completion And Resubmission Of The Apadaz NDA
8/10/2017 7:33:08 AM KemPharm Announces Preliminary Results From KP415 Pharmacokinetic Single And Multiple Dose Trial
8/8/2017 7:47:05 AM KemPharm Publishes Study Of Intranasal Abuse Of Hydrocodone Combination Products In Pharmacoepidemiology & Drug Safety
3/16/2017 7:37:52 AM KemPharm Presents Clinical Data From Two Of Its Opioid Prodrug Candidates, KP511 And KP201/IR
1/9/2017 7:39:45 AM KemPharm Reports Positive Data From Phase 1 Intranasal Pharmacokinetic Study Of KP511
12/20/2016 7:33:42 AM KemPharm Says FDA Grants “Fast Track” Designation To Its INDA For KP201/IR
11/29/2016 7:32:32 AM KemPharm Receives Clearance From FDA To Initiate Clinical Program For KP201/IR
11/10/2016 6:46:54 AM RBC Capital Markets Is Lowering KEMPHARM, INC (KMPH) Q4 16 Estimate To -0.76 From -0.68
11/10/2016 6:46:28 AM RBC Capital Markets Is Lowering KEMPHARM, INC (KMPH) 2018 Estimate To -1.92 From -1.85
11/10/2016 6:46:15 AM RBC Capital Markets Is Cutting KEMPHARM, INC (KMPH) 2017 Estimate To -2.93 From -2.83